RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM
Clinical trials for RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Matched conditions: RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for recurrent ovarian and endometrial cancers? drug tazemetostat under study
Disease control OngoingThis phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…
Matched conditions: RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…
Matched conditions: RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT MALIGNANT UTERINE CORPUS NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 04:00 UTC